Healthcare agency Havas Health & You is launching a new “access” consultancy that looks to help steer biopharma through the tumultuous seas of pricing, access and reimbursement issues for their products.
Dubbed Archipelago, this is HH&Y’s first standalone consultancy firm that wants to take clients’ hands as they seek to get the market price they need for their drugs and medical devices.
Headed up by the agency’s managing partner, Michael Pill, Archipelago comes out of Havas Gemini, the value and access center of excellence for HH&Y, and also comes with an expert rota of staffers in the access, value and reimbursement field.
The agency said in a press release that Archipelago “offers a breadth of experience in payer, manufacturer, agency, consulting, and clinical practice settings, and across a range of therapeutic areas and acquisition models, including chronic, small molecule, buy-and-bill, gene, orphan, and digital health.”
“As a business that services clients across issue areas at a global scale, it's critical that we both understand and are able to solve complex market and brand problems effectively and efficiently,” Donna Murphy, CEO of Havas Creative Group and HH&Y, said in the release.
It’s been a busy year for the agency. HH&Y teamed up with life sciences consultancy Trinity Life Sciences in January and Evermed in December, while taking on Elizabeth Egan as its CEO of Europe last summer.